MedTrace Logo

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

NCT01654185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-03-14

No results posted yet for this study

Summary

The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic breast cancer.

Conditions

Interventions

DRUG

AI plus Dimethyldiguanide

AI 1 tablet per day Dimethyldiguanide 0.5 bid

DRUG

Aromatase Inhibitor

1 tablet per day

Sponsors & Collaborators

  • Xichun Hu

    lead OTHER

Principal Investigators

  • Xichun Hu, MD,PhD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-07-31
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01654185 on ClinicalTrials.gov